Toronto life sciences spin-out Xagenic closes $20m series B ahead of FDA submission.
Xagenic, a University of Toronto spin-out developing a lab-free molecular diagnostic platform, has raised a $20m series B. The round was led by new investor and venture firm Domain Associates, and joined in participation by existing backers venture firm CTI Capital and the Ontario Emerging Technologies Fund. Including a 2012 series A round, which saw…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
